Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
Chest. 2015 May;147(5):e185-e188. doi: 10.1378/chest.14-1443.
A 25-year-old woman, a never smoker with a history of heart-lung transplantation for World Health Organization group 1 pulmonary arterial hypertension performed 20 months prior to presentation, was evaluated for shortness of breath. Following transplantation, she was initiated on standard therapy of prednisone, tacrolimus, and azathioprine, along with routine antimicrobial prophylaxis. Her posttransplant course was complicated by persistent acute cellular rejection, as determined from a transbronchial biopsy specimen, without evidence of rejection in an endomyocardial biopsy specimen. The immunosuppressive medications were supplemented with pulse-dosed steroids, and the patient was transitioned from azathioprine to mycophenolate mofetil. Sirolimus was added 9 months prior to presentation. Three months prior to presentation, she was admitted for increasing oxygen requirements, shortness of breath, and bilateral infiltrates on the CT scans of the chest.
一位 25 岁女性,既往无吸烟史,曾因世界卫生组织 1 组肺动脉高压行心肺联合移植,于 20 个月前就诊,因呼吸困难就诊。移植后,她接受了标准治疗,包括泼尼松、他克莫司和硫唑嘌呤,以及常规的抗菌预防。她的移植后病程复杂,存在持续的急性细胞排斥,这是从支气管活检标本中确定的,而心内膜活检标本中没有排斥的证据。免疫抑制药物补充脉冲剂量类固醇,患者从硫唑嘌呤转换为霉酚酸酯。西罗莫司在就诊前 9 个月添加。就诊前 3 个月,她因氧需求增加、呼吸困难和胸部 CT 扫描显示双侧浸润而住院。